| 1. |
Wada K, Hosokawa K, Ito Y, Maeda M, Harada Y, Yonemitsu Y., Generation of transmitochondrial cybrids using a microfluidic device, Exp Cell Res, 2022.06. |
| 2. |
Sasaki K, Harada M, Yoshikawa T, Tagawa H, Harada Y, Yonemitsu Y, Ryujin T, Kishimura A, Mori T, Katayama Y., Fc-binding antibody-recruiting molecules targeting prostate-specific membrane antigen: defucosylation of antibody for efficacy improvement, ChemBioChem, 22, 496-500, 2021.06. |
| 3. |
Nagai K, Harada Y, Harada H, Yanagihara K, Yonemitsu Y, Miyazaki Y., Highly activated ex vivo-expanded natural killer cells in patients with solid tumors in a Phase I/IIa clinical study, Anticancer Res., 5687-5700, 40:5687-5700, 2020.06. |
| 4. |
Touyama K, Khan M, Aoki K, Matsuda M, Hiura F, Takakura N, Matsubara T, Harada Y, Hirohashi Y, Tamura Y, Gao J, Mori K, Kokabu S, Yasuda H, Fujita Y, Watanabe K, Takahashi Y, Maki K, Jimi E, Bif-1/Endophilin B1/SH3GLB1 regulates bone homeostasis
, J Cell Biochem, 2019.06. |
| 5. |
Akamine T, Morodomi Y, Harada Y, Teraishi K, Tagawa T, Okamoto T, Maehara Y, Yonemitsu Y.
, miR-3148 is a novel onco-microRNA that potentiates tumor growth in vivo., Anticancer Res , 38:5693-5701, 2018.10. |
| 6. |
Kawakubo N, Harada Y*, Ishii M, Souzaki R, Kinoshita Y, Tajiri T, Taguchi T, Yonemitsu Y.
, Natural antibody against neuroblastoma of TH-MYCN transgenic mice does not correlate with spontaneous regression.
, Biochem Biophys Res Commun, 503:1666-1673, 2018.09. |
| 7. |
Iwai T, Harada Y, Saeki H, Oki E, Maehara Y, Yonemitsu Y.
, Capecitabine reverses tumor escape from anti-VEGF through the eliminating CD11bhigh/Gr1high myeloid cells, Oncotarget, 9:17620-17630, 2018.04. |
| 8. |
Murakami A, Matsuda M, Harada Y, Hirata M.
, Phospholipase C-related, but catalytically inactive protein (PRIP) upregulates osteoclast differentiation via calcium-calcineurin-NFATc1 signaling.
, Journal of Biological Chemistry , 12:7994-8006, 2017.05. |
| 9. |
Tanaka S, Matsumoto T, Matsubara Y, Harada Y, Kyuragi R, Koga J, Egashira K, Nakashima Y, Yonemitsu Y, Maehara Y.
, BubR1 insufficiency results in decreased macrophage proliferation and attenuated atherogenesis in apolipoprotein E-deficient mice., Journal of the American Heart Association , 2016.09. |
| 10. |
Kasagi Y*, Harada Y*, Morodomi Y, Saito S, Yoshida K, Oki E, Saeki K, Ohgaki K, Sugiyama M, Onimaru M, Maehara Y, Yonemitsu Y.
, Peritoneal dissemination requires an Sp1-dependent CXCR4/CXCL12 signaling axis and extracellular matrix-directed spheroid formation.
, Cancer Research, 76:347-57, 2016.01. |
| 11. |
Kimura Y, Harada Y*, Yasuda N, Ishidao T, Yusa S, Matsusaki K, Yonemitsu Y.
, Effective recovery of highly purified CD326+ tumor cells from lavage fluid of patients treated with a novel cell-free and concentrated ascites reinfusion therapy (KM-CART).
, SpringerPlus, 4:780, 2015.12. |
| 12. |
Kyuragi R, Matsumoto T, Harada Y, Saito S, Onimaru M, Nakatsu Y, Tsuzuki T, Nomura M, Yonemitsu Y, Maehara Y.
, BubR1 insufficiency impairs vascular smooth muscle cell proliferation and inhibits neointimal hyperplasia in mice.
, Arteriosclerosis Thrombosis and Vascular Biology, 35:341-347, 2015.03. |
| 13. |
Saito S, Harada Y, Morodomi Y, Onimaru M, Yoshida K, Matsubara H, Yonemitsu Y., Ex vivo generation of highly purified and activated NK cells from human peripheral blood., Human Gene Therapy Method, 24,241-252, 2013.08. |
| 14. |
Morodomi Y, Yano T, Kinoh H, Harada Y, Saito S, Kyuragi R, Yoshida K, Onimaru M, Shoji F, Yoshida T, Ito K, Shikada Y, Maruyama R, Hasegawa M, Maehara Y, Yonemitsu Y., BioKnife, a uPA Activity-dependent Oncolytic Sendai Virus, Eliminates Pleural Spread of Malignant Mesothelioma via Simultaneous Stimulation of uPA Expression., Molecular Therapy, 4, 769-777, 2012.02. |
| 15. |
Sugiyama M, Kakeji Y, Tsujitani S, Harada Y, Onimaru M, Yoshida K, Tanaka S, Emi Y, Morita M, Morodomi Y, Hasegawa M, Maehara Y, Yonemitsu Y., Antagonism of VEGF by genetically engineered dendritic cells is essential to induce antitumor immunity against malignant ascites., Molecular Cancer Therapy, 10, 540-549, 2011.03. |
| 16. |
Matsunaga A, Ueda Y, Yamada S, Harada Y, Shimada H, Hasegaw M, Tsuji H, Ochiai T, Yonemitsu Y., Carbon ion beam treatment induces systemic antitumor immunity against murine squamous cell carcinoma., Cancer, 116, 3740-3748, 2010.08. |
| 17. |
Kato T, Ueda Y, Kinoh H, Yoneyama Y, Matsunaga A, Komaru A, Harada Y, Suzuki H, Komiya A, Shibata S, Hasegawa M, Hayashi H, Ichikawa T and Yonemitsu Y., RIG-I helicase-independent pathway in sendai virus-activated dendritic cells is critical for preventing lung metastasis of AT6.3 prostate cancer., Neoplasia, 12, 906-914, 2010.11. |
| 18. |
Harada Y, Ueda Y, Kinoh H, Komaru A, Fuji-Ogawa T, Furuya A, Iida A, Hasegawa M, Ichikawa T, Yonemitsu Y., Cytokine-based log-scale expansion of functional murine dendritic cells., PLos ONE, 4:e6674, 2009.08. |
